Background and Aims: The technique and method of pancreaticojejunostomy are important influential factors for the occurrence of pancreatic fistula after pancreaticoduodenectomy (PD). However, none of the pancreaticojejunostomy procedures has a superiority over others in reducing the incidence of postoperative pancreatic fistula so far. This study was conducted to investigate the efficacy and safety using the modified Blumgart pancreaticojejunostomy developed by the authors’ team in PD. 
Methods: A retrospective historical control study was performed, which included 55 patients undergoing the conventional invagination pancreaticojejunostomy after PD during August 2014 to January 2017 (conventional group) and 53 patients undergoing the modified Blumgart pancreaticojejunostomy after PD from February 2017 to August 2019 (modified group). The main clinical variables and the incidence rates of postoperative complications were compared between the two groups of patients.
Results: There were no significant differences in preoperative clinical data, total operative time, operative time for pancreaticojejunostomy and intraoperative blood loss as well as the incidence rates of bile leakage and delayed gastric emptying between the two groups (all P>0.05). The incidence rates of postoperative complications that included pancreatic fistula, abdominal hemorrhage and abdominal infection in modified group were significantly lower than those in conventional group (all P<0.05). Biochemical leakage occurred in 4 cases (7.5%) and B/C pancreatic fistula occurred in 3 cases (5.7%) in modified group, while biochemical leakage occurred in 12 cases (21.8%) and B/C pancreatic fistula occurred in 10 cases (18.2%) in conventional group; no abdominal hemorrhage and infection as well as death occurred in modified group, while there were 8 cases of abdominal hemorrhage, 7 cases of abdominal infection and 4 cases of death in traditional group.
Conclusion: Using the modified Blumgart pancreaticojejunostomy can effectively reduce the incidence rates of pancreatic fistula, abdominal bleeding and abdominal infection, so it has certain clinical application value. However, this conclusion still needs to be verified by multi-center prospective clinical studies.